Spark Therapeutics to Participate in Multiple Conferences in January
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain on Iran ceasefire hopes; earnings in focus
- Oil prices firm as investors weigh fresh attacks against potential US-Iran ceasefire
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Spark Therapeutics (ONCE) PT Lowered to $55 at Goldman Sachs Following US Pricing of Luxturna
January 4, 2018 8:04 AM ESTGoldman Sachs lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $55.00 (from $58.00) while maintaining a Neutral rating following the company's announcement that US pricing of lead gene therapy Luxturna is at $425K/eye (gross), below GSe of $500K/eye.
Goldman Sachs now... More
